The aim of this observational study was to describe usual practices in lymphedema management in France.

It was the opportunity to assess the effects of these practices on lymphedema volume in a large number of patients, to identify predictive factors of response, and to assess the safety of this therapy.

Lymphoedema is commonly treated according a strategy called Complex Decongestive Therapy (CDT). This CDT is usually composed of 2 different treatment phases. The first phase is an acute phase which aim is to reduce affected limb volume. The second phase is a maintenance phase which aim is to maintain as long as possible the volume reduction acheived during the first phase.

These 2 phases required multi modal parameters such as bandages, lymphatic drainages, physical exercises...and can be managed very differently from one site to another.

Inclusion Criteria:

• consecutive adult patients
• hospitalized with a clinical diagnosis of unilateral stage II-III upper or lower limb lymphoedema of any etiology
• indication for intensive decongestive therapy (IDT)

Exclusion Criteria:

• bilateral lymphedema,
• lymphedema of both upper and lower limbs,
• intensive decongestive therapy in the previous 6 months,
• cancer recurrence,
• systolic pressure index < 0.5

All consecutive adult patients hospitalized with a clinical diagnosis of unilateral stage II-III upper or lower limb lymphoedema of any etiology and an indication for intensive decongestive therapy (IDT) were enrolled.